Skip to contentpdufa.bio

Zervimesine

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

Zervimesine is a Cognition Therapeutics Inc program in mild cognitive impairment and early Alzheimer's disease. Its next catalyst is a Readout in Q4 2027.

CGTX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Mild cognitive impairment and early Alzheimer's disease. Sponsor: Cognition Therapeutics Inc (CGTX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027CGTX

Questions

When is Zervimesine's next FDA decision or readout?

The next tracked catalyst for Zervimesine is a Readout in Q4 2027.

What happened at Zervimesine's most recent FDA decision?

No FDA decision for Zervimesine is in our archive yet.

What is Zervimesine used for?

In our records Zervimesine is under review or in development for Mild cognitive impairment and early Alzheimer's disease.

Who makes Zervimesine?

Cognition Therapeutics Inc (CGTX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.